# Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

> **NCT03036904** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 31 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Rituximab
- **DRUG:** Etoposide
- **DRUG:** Vincristine Sulfate
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Doxorubicin Hydrochloride

## Key facts

- **NCT ID:** NCT03036904
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2021-11-11
- **Final completion:** 2021-11-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03036904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03036904, "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03036904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*